Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Portfolio Pulse from
STERIS has been upgraded to a 'Buy' with a fair value of $240 per share due to a recent stock price pullback and strong growth prospects. The company reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with notable performance in the Applied Sterilization Technologies segment.
November 18, 2024 | 2:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
STERIS has been upgraded to a 'Buy' with a fair value of $240 per share. The company reported strong growth in its Applied Sterilization Technologies segment, with 7.2% organic revenue growth and 5.4% adjusted EPS growth.
The upgrade to 'Buy' and the fair value of $240 per share suggest positive sentiment and potential upside for STERIS. The reported growth in organic revenue and adjusted EPS, particularly in the AST segment, supports this outlook. The anticipated recovery in the biotech industry could further drive revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100